Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513385 | 0.87 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ACYP1A2CTSD | |
| SCHEMBL31530477 | 0.75 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ACYP1A2CTSD | |
| SCHEMBL31530473 | 0.75 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ACYP1A2CTSD | |
| SCHEMBL7475644 | 0.74 | GLA (0.53) | ALDH1A1MEN1KMT2ACYP1A2CTSD | |
| SCHEMBL7475632 | 0.74 | GLA (0.53) | ALDH1A1MEN1KMT2ACYP1A2CTSD | |
| SCHEMBL13761295 | 0.74 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ACYP1A2CTSD | |
| Morpholine SCHEMBL4870083 | 0.74 | MAPT (0.49) | ALDH1A1MEN1KMT2ACYP1A2KDM4E | |
| SCHEMBL5065347 | 0.73 | MAPT (0.57) | ALDH1A1MEN1KMT2AKDM4ECYP2C19 | |
| SCHEMBL8026101 | 0.73 | ALDH1A1 (0.65) | ALDH1A1MEN1KMT2ACYP1A2CTSD | |
| SCHEMBL4285030 | 0.72 | LMNA (0.64) | ALDH1A1MEN1KMT2ACYP1A2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242115-B2 | Inhibit DNA-dependent protein kinase; reduced side effects caused by radiation and chemotherapy drugs | LUITPOLD PHARMACEUTICALS, INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-7179912-B2 | Materials and methods to potentiate cancer treatment | ICOS CORPORATION (US) | 2007-02-20 | — | — | US | disclosed |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | LUITPOLD PHARMACEUTICALS, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090782-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | ALDH1A1 3519/4885MEN1 2946/4885KMT2A 1686/4885 |
| US-20020165218-A1 | Materials and methods to potentiate cancer treatment | DCK, CHEK2, CHEK1 | ALDH1A1 3519/4885MEN1 2946/4885KMT2A 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.